Newly licensed drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.Cardiovascular diabetology · 2022
   Pooled it
2. Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials.European journal of clinical nutrition · 2016
   Pooled it
3. Drug safety assessment in clinical trials: methodological challenges and opportunities.Trials · 2012
   Review
4. Antibiotics and allergic disorders in childhood.The open nursing journal · 2008
   Article
5. How NICE may be outflanked.BMJ (Clinical research ed.) · 2006
   Review
6. The influence of big pharma.BMJ (Clinical research ed.) · 2005
   Article
7. Failures of the therapeutic chain as a cause of drug ineffectiveness.BMJ (Clinical research ed.) · 2003
   Article
8. Prescribing new drugs: qualitative study of influences on consultants and general practitioners.BMJ (Clinical research ed.) · 2001
   Article
9. The quantity and quality of clinical practice guidelines for the management of depression in primary care in the UK.The British journal of general practice : the journal of the Royal College of General Practitioners · 1999
   Article
10. The need for pharmacoeconomic evaluations in the NHS.PharmacoEconomics · 1998
    Article
11. Health technology assessment--the role of the pharmaceutical panel.British journal of clinical pharmacology · 1998
    Article

Corrections and comments

• Commented on by
  Newly licensed drugs. Doctors should be encouraged to report adverse reactions.1997
• Commented on by
  Interferon beta in multiple sclerosis. Some form of compromise must be accepted.1997
• Commented on by
  New antiepileptic drugs. Register of women who take the drugs during pregnancy has been set up.1997
• Commented on by
  Newly licensed drugs. A probationary period is a good idea.1997
• Commented on by
  Newly licensed drugs. Randomised controlled trials are needed in primary care before new drugs are licensed.1997
• Commented on by
  Newly licensed drugs. "Proportionate benefits" should be made clear.1997
• Commented on by
  Interferon beta in multiple sclerosis. Current policy is sensible.1997
• Commented on by
  Interferon beta in multiple sclerosis. Interferon beta reduces overall relapse rate by one third.1997
• Commented on by
  Interferon beta in multiple sclerosis. Avoidance of the need for social care should also be taken into account.1997
• Commented on by
  Interferon beta in multiple sclerosis. Relapses deserve treatment.1997
• Comment on
  Interferon beta in multiple sclerosis.1996
• Comment on
  New antiepileptic drugs: a systematic review of their efficacy and tolerability.1996
• Comment on
  Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome.1996
• Comment on
  A purchaser experience of managing new expensive drugs: interferon beta.1996
• Comment on
  Drug trials in epilepsy.1996

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as